Clinical experience in more than 2000 patients with myasthenia gravis.
The vast strides in terms of pathophysiologic understanding which have been made in the past 25 years of research in myasthenia gravis are remarkable. This period of time has also seen the evolution of many applicable technological advances to better our care of these patients. Myasthenia's place in the autoimmune family of diseases has been demonstrated. No clear-cut strategy resulting from these discoveries has, however, been more than one of temporary relief or clinical improvement. In our center over these years the performance of early thymectomy in all cases of generalized myasthenia seems to be the one demonstrably reliable technique available. The effect of this procedure on coexisting neoplasia and other autoimmune disease suggests continuing avenues of investigation.
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D009369:Neoplasms / Q000150:complications; D010956:Plasmapheresis; D011247:Pregnancy; D011248:Pregnancy Complications / Q000628:therapy; D013514:Surgical Procedures, Operative; D013934:Thymectomy; D005719:gamma-Globulins / Q000627:therapeutic use
D002800:Cholinesterase Inhibitors; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D005719:gamma-Globulins; D000324:Adrenocorticotropic Hormone